

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060281 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2003/039351
- (22) International Filing Date:
11 December 2003 (11.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/435,970 20 December 2002 (20.12.2002) US
- (71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; P. O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors: **BOY, Kenneth, M.**; 50R Deer Run Road,
Durham, CT 06422 (US). **WU, Yong-Jin**; 228 Devonshire
Lane, Madison, CT 06443 (US). **GUERNON, Jason, M.**;
270 Magee Drive, Hamden, CT 06514 (US).
- (74) Agents: **EPPERSON, James et al.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: 2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS



(57) Abstract: Novel 2-arylthiazole derivatives of Formula (I) are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine.

WO 2004/060281 A2

2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS

REFERENCE TO RELATED APPLIATIONS

5 This application claims the benefit of U.S. provisional application No. 60/435970, filed December 20, 2002.

BACKGROUND OF THE INVENTION

10 The present invention is directed to novel 2-arylthiazole compounds which are modulators of KCNQ potassium channels and are useful in treating disorders responsive to the modulation of the potassium channels. The invention also provides pharmaceutical compositions and methods of treatment with the novel 2-arylthiazole compounds.

15 Potassium (K^+) channels are a diverse class of ion channels and have several critical roles in cell function. One role is in neurons, where K^+ channels are responsible, in part, for determining cell excitability by contributing to membrane repolarization following depolarization, resting membrane potential, and regulation
20 of neurotransmitter release. The M-current, measured by electrophysiology recording methods and by pharmacology, has been described as a dominant conductance in controlling neuronal excitability. Pharmacological activation or suppression of M-currents by small molecules could have profound effects in controlling neuronal excitability. Recently, Wang reported that co-assembly of the
25 KCNQ2 and KCNQ3 potassium channels underlies the native M-current in neurons (Wang et al., *Science* 1998, 282, 1890-1893).

 Activation or opening of the KCNQ channels, particularly the KCNQ2 or KCNQ2/3 channels, mutated or wild type, may be beneficial for increasing
30 hyperpolarization of neurons, thereby resulting in protection from abnormal synchronous firing during a migraine attack. This invention provides a solution to the problem of abnormal synchronous firing of neurons related to migraine headache by demonstrating that modulators, preferably openers, of KCNQ potassium channels

increase hyperpolarization of neurons. This leads to protection against abnormal synchronous neuron firing involved in migraine attacks.

Although the symptom pattern varies among migraine sufferers, the severity
5 of migraine pain justifies a need for vigorous, yet safe and effective, treatments and
therapies for the great majority of cases. A need exists for agents that can be used to
combat and relieve migraine (and diseases similar to and mechanistically related to
migraine), as well as prevent the recurrence of migraine. Also needed are abortive
anti-migraine agents, effective in the treatment of acute migraine, as well as in the
10 prodrome phase of a migraine attack. Thus, a clear goal in the art is to discover new,
safe, nontoxic and effective anti-migraine compounds and their pharmaceutical
compositions for use in anti-migraine treatments.

Because migraine afflicts a large percentage of the population, there is a need
15 to discover compounds and agents that are useful in therapeutics and treatments, and
as components of pharmaceutical compositions, for treating the pain and discomfort
of migraine headache and other symptoms of migraine. This invention satisfies this
need by providing compounds that function as openers of the KCNQ family of
potassium ion channels and act as anti-migraine agents.


20

A number of thiazole derivatives have been disclosed. These references do
not teach or suggest the compounds of this invention. See the following: WO
01/40207 A1, JP 04128275 A2, US 5,244,867, US 4,980,363, US 5,846,990, JP
04049290 A2, WO 99/66925 A1, US 5,888,941, US 3,794,636, JP 57183768 A2, US
25 5,057,142, US 5,859,035, JP 02229190 A2, WO 98/28282 A2, WO 00/06085 A2, US
5,614,520, US 3,689,481, JP 01250379 A2, US 3,872,124, US 4,923,886, WO
99/59570 A1, WO 01/10798 A1, and WO 95/19972 A1.

SUMMARY OF THE INVENTION

The invention encompasses novel 2-arylthiazole compounds and related derivatives of Formula I.

5



I


The compounds are openers or activators of KCNQ potassium channels. The invention also describes pharmaceutical compositions and methods of treating disorders sensitive to KCNQ potassium channel opening activity.

10

DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses compounds of Formula I and related derivatives, including pharmaceutically acceptable salts and solvates,

15



I

20


where:

Q¹ is CH or N;

Ar¹ is selected from the group consisting of

25

4



R^1 is hydrogen, C_{1-6} alkyl, hydroxymethyl, or trifluoromethyl;


5

R^2 is halogen, C_{1-6} alkyl, C_{1-2} perfluoroalkyl, C_{1-6} alkoxy, C_{1-2} perfluoroalkoxy, $-NR^6R^7$, $-(CH_2)_{1-4}NR^6R^7$, $-O(CH_2)_{2-3}NR^6R^7$, or pyridyl;

R^3 is hydrogen, halogen, or C_{1-6} alkoxy;



10

R^4 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, $-NR^6R^7$, $-(CH_2)_{1-4}NR^6R^7$, $-O(CH_2)_{2-3}NR^6R^7$, or



R^5 is hydrogen, halogen, or C_{1-6} alkoxy;

15

R^6 is hydrogen, C_{1-6} alkyl, $-C(=NH)NH_2$, , or ;

R^7 is hydrogen or C_{1-6} alkyl;

20 or R^6 and R^7 taken together are $-CH_2CH(CH_3)OCH(CH_3)CH_2-$ or $-CH_2CH_2XCH_2CH_2-$, where X is a chemical bond, CH_2 , $CHOH$, NH , NCH_3 , $NCOCH_3$, O, or S.

25 “ C_{1-6} alkyl” means straight or branched chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and *tert*-butyl. “ C_{1-6} alkoxy” means an oxygen substituted with straight or branched chain alkyl groups and includes groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and *tert*-butoxy.

“KCNQ” means the family of polypeptides that have been described as KCNQ2, KCNQ3, KCNQ4, and KCNQ5 potassium channels as well as heteromultimers of different members. For example, KCNQ2/3, KCNQ2/5 and KCNQ3/5.

5

The term “pain” includes all types of acute and chronic pain, such as migraine or a migraine attack, cluster headaches, musculoskeletal pain, post-operative pain, surgical pain, inflammatory pain, neuropathic pain such as diabetic neuropathy and pain associated with cancer and fibromyalgias, chronic lower back pain, herpes
10 neuralgia, phantom limb pain, central pain, dental pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, including sunburn, post partum pain, migraine, angina pain, and genitourinary tract-related pain including cystitis. The term is also intended to include nociceptive pain or nociception.

15


“Therapeutically effective amount” means the amount of a compound required to elicit a meaningful patient benefit. For example, the amount of compound or composition necessary to improve a clinical parameter or ameliorate a symptom.

20

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made
25 according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium,
30 aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

The invention also includes all solvated forms of the instant compounds, particularly hydrates. Solvates do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. Solvates may form in stoichiometric amounts or may form from adventitious solvent or a combination of both. One type of solvate is hydrate, and some hydrated forms include monohydrate, hemihydrate, and dihydrate.


Some of the compounds of the invention possess asymmetric carbon atoms, such as the carbon atom bearing R^1 in Formula Ia. The invention includes all stereoisomeric forms. Stereoisomeric mixtures of the compounds and related intermediates can be separated into individual isomers according to methods commonly known in the art.



Ia


One aspect of the invention includes compounds of Formula I where Q^1 is CH.

Another aspect of the invention are compounds of Formula I where Ar^1



is


Another aspect of the invention are compounds of Formula I where Ar^1 is




Another aspect of the invention are compounds of Formula I where R^1 is hydrogen or methyl.

Another aspect of the invention are compounds of Formula Ig.

7



Another aspect of the invention are compounds of Formula I where R¹ is
 5 C₁₋₆alkyl and the compound is that of Formula Ia.



10 Some compounds of the invention include the following:

- (1) 2-(4-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 15 (2) 2-(2-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (3) 2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 20 (4) 2-(2-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (5) 2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 25 (6) 2-(2-methoxyphenyl)-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (7) 2-(3-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (8) N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (9) N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(2-fluorophenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (10) N-[(3-fluorophenyl)methyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (11) 2-(4-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (12) 2-(3,4-dimethoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (13) 2-(2,4-dimethoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (14) 2-(2,4-dimethoxyphenyl)-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (15) 2-(2-methoxyphenyl)-N-[1-[3-(1-piperidinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (16) 2-(2-methoxyphenyl)-N-[1-[3-(1-pyrrolidinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (17) N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (18) 2-(2-fluorophenyl)-N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (19) 2-(3,4-dimethoxyphenyl)-N-[1-[3-(1-pyrrolidinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (20) 2-(2-fluorophenyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (21) N-[1-(3-aminophenyl)ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (22) N-[1-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (23) 2-(5-fluoro-2-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (24) N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (25) 2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (26) 2-(5-fluoro-2-methoxyphenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (27) 2-(5-fluoro-2-methoxyphenyl)-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (28) 2-(5-fluoro-2-methoxyphenyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (29) 2-(5-fluoro-2-methoxyphenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (30) 2-(5-fluoro-2-methoxyphenyl)-N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-4-
5 (trifluoromethyl)-5-thiazolecarboxamide;
- (31) 2-(2-chlorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (32) 2-(2-chlorophenyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-4-
10 (trifluoromethyl)-5-thiazolecarboxamide;
- (33) 2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
15
- (34) 2-(2-chlorophenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (35) 2-(2-chlorophenyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-
20 (trifluoromethyl)-5-thiazolecarboxamide;
- (36) 2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (37) N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-2-[2-(4-morpholinyl)phenyl]-4-
25 (trifluoromethyl)-5-thiazolecarboxamide;
- (38) 2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
30
- (39) 2-[2-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (40) 2-[4-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (41) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (42) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (43) 2-[2-[(dimethylamino)methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (44) 2-[2-[(dimethylamino)methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (45) 2-[2-[(dimethylamino)methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (46) 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (47) 2-[2-[(diethylamino)methyl]phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (48) 2-[2-[(diethylamino)methyl]phenyl]-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (49) 2-[2-[(diethylamino)methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (50) 2-[2-[(diethylamino)methyl]phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (51) 2-[2-[(diethylamino)methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (52) 2-(4-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (53) 2-(2-methoxyphenyl)-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (54) N-[(3-fluorophenyl)methyl]-2-(3-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (55) N-[1-(2,3-dihydro-5-benzofuranyl)ethyl]-2-(3-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (56) 2-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (57) 2-(3,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (58) 2-(3,4-dimethoxyphenyl)-N-[1-(3,4-dimethoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (59) 2-(3,4-dimethoxyphenyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (60) 2-(3-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (61) 2-(2,4-dimethoxyphenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (62) 2-(3-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (63) N-[1-(3-bromophenyl)ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (64) 2-[3-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (65) 2-[3-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (66) N-[(1S)-1-(3-methoxyphenyl)ethyl]-2-[3-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (67) 2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (68) 2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (69) N-[1-(3-aminophenyl)ethyl]-2-(2-fluorophenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (70) 2-[2-[2-(diethylamino)ethoxy]-5-fluorophenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (71) 2-[2-[(dimethylamino)methyl]phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (72) 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (73) 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (74) 2-[2-(4-morpholinylmethyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (75) 2-[2-(4-morpholinylmethyl)phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (76) 2-[2-(4-morpholinylmethyl)phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (77) 2-(3-fluorophenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (78) N-[(1S)-1-(3-methoxyphenyl)ethyl]-2-[2-(4-morpholinylmethyl)phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (79) N-[(1S)-1-(3-methoxyphenyl)ethyl]-2-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (80) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (81) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (82) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (83) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (84) 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (85) 2-(2-methylbenzoyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (86) N-[1-[4-fluoro-3-(4-morpholinyl)phenyl]ethyl]-2-(2-methylbenzoyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (87) 2-[3-[(diethylamino)methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (88) 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (89) 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (90) N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (91) N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (92) N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (93) 2-[3-(4-morpholinylmethyl)-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- (94) 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 5 (95) 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (96) 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 10 (97) 2-[3-[(diethylamino)methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- (98) 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 15 (99) 2-(3-methyl-2-pyridinyl)-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (100) 2-(3-methyl-2-pyridinyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-
- 20 (trifluoromethyl)-5-thiazolecarboxamide;
- (101) 2-[3-(1,3-dioxolan-2-yl)-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 25 (102) 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- (103) 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 30 (104) 2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

(105) 2-benzo[b]thien-3-yl-N-[1-[3-(1-pyrrolidinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

(106) 2-(1,3-benzodioxol-5-yl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

(107) N-[1-[3-[(diethylamino)methyl]phenyl]ethyl]-2-(1-naphthalenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide; and

(108) 2-(1,3-benzodioxol-5-yl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

and pharmaceutically acceptable salts and solvates of these compounds.

15


Synthetic Methods

The general procedures used to synthesize intermediates and the compounds of Formula I are illustrated in Schemes 1-4 and are described in detail in the Specific Embodiments section. Reasonable variations of the described procedures, which would be evident to one skilled in the art, are intended to be within the scope of the present invention.

Scheme 1 illustrates a general route to Formula I compounds. Bromothiazole III can be coupled to an aryl boronic acid under Suzuki conditions to provide compounds of Formula II. Although Scheme 1 employs an aryl boronic acid in the Suzuki coupling reaction, other aryl organometallic compounds, such as organostannanes, are well known to undergo transition metal catalyzed couplings of this type. Hydrolysis of the ester moiety followed by amination of the resulting carboxylic acid generates compounds of Formula I.

30

Scheme 1.




Scheme 2 illustrates the preparation of Formula Ib and Ic compounds.

- 5 Methoxy compounds of Formula IIa, which encompass both phenyl and pyridyl moieties of Ar^1 , are demethylated with boron tribromide to generate phenols of Formula IIb. These phenols can be transformed into Formula Ib compounds by alkylating with dibromoethane followed by amination with amines of Formula HNR^6R^7 to give thiazoles IId. Hydrolysis followed by amination as described before
- 10 provides compounds of Formula Ib.

Phenols of Formula IIb can also be triflated followed by palladium catalyzed amination with HNR^6R^7 to generate thiazoles of Formula IIe. Hydrolysis and amination as described before provides compounds of Formula Ic.


Scheme 2.



Scheme 3 provides a method for preparing compounds of Formula Id, Ie, and If. Aldehydic aryl bromides of Formula IV, which encompass both phenyl and pyridyl moieties of Ar^1 , are protected as their ketals followed by transforming the aryl bromide moiety into an aryl stannane. The stannanes are coupled with thiazole III under Stille conditions to provide compounds of Formula IIg. Hydrolysis


followed by amination as described before generates Formula Id compounds. The ketals are deprotected and reductively aminated to provide Formula If compounds.

Scheme 3.



Scheme 4 illustrates an additional method for generating Formula If compounds. Compound IIh, prepared via Scheme 1 with a commercially available boronic acid, is cleaved with osmium tetroxide and periodate to generate aldehydes of Formula Iii. Reductive amination generates compounds of Formula Iij. Hydrolysis followed by amination as described before provides Formula If compounds.

Scheme 4.



5

Biological Methods

Potassium (K⁺) channels are structurally and functionally diverse families of K⁺-selective channel proteins which are ubiquitous in cells, indicating their central importance in regulating a number of key cell functions [Rudy, B., Neuroscience, 25: 729-749 (1988)]. While widely distributed as a class, K⁺ channels are differentially distributed as individual members of this class or as families. [Gehlert, D.R., et al., Neuroscience, 52: 191-205 (1993)]. In general, activation of K⁺ channels in cells, and particularly in excitable cells such as neurons and muscle cells, leads to hyperpolarization of the cell membrane, or in the case of depolarized cells, to repolarization. In addition to acting as an endogenous membrane voltage clamp, K⁺ channels can respond to important cellular events such as changes in the intracellular concentration of ATP or the intracellular concentration of calcium (Ca²⁺). The central role of K⁺ channels in regulating numerous cell functions makes them particularly important targets for therapeutic development. [Cook, N.S., Potassium channels: Structure, classification, function and therapeutic potential. Ellis

Horwood, Chinchester (1990)]. One class of K⁺ channels, the KCNQ family exemplified by KCNQ2, KCNQ2/3 heteromultimers, and KCNQ5, is regulated by transmembrane voltage and plays a potentially important role in the regulation of neuronal excitability [Biervert, C., et al., Science, 279: 403-406 (1998); Lerche, C. et al., J. Biol. Chem. 275:22395-22400 (2000); Wang, H. et al., Science, 282:1890-1893 (1998)].

An opener of KCNQ channels, such as the KCNQ2 and KCNQ2/3 channel opener retigabine, exerts its cellular effects by increasing the open probability of these channels [Main J., Mol Pharmacol 58(2):253-62 (2000); Wickenden, A. et al., Mol. Pharm. 58:591-600 (2000)]. This increase in the opening of individual KCNQ channels collectively results in the hyperpolarization of cell membranes, particularly in depolarized cells, produced by significant increases in whole-cell KCNQ-mediated conductance.

15

Thallium Flux Assay for KCNQ channel Openers. The thallium assay is a modification of that published by Weaver and is referenced in its entirety (Weaver, C. D. WO 02/31508, 2002).

Approximately 20,000 cells/well of an HEK-293 cell line stably transfected with one of the members of the KCNQ family were plated into clear-bottom, black-walled, poly-D-lysine coated, 384 well assay plates in 20 µl/well of low chloride plating medium. Low chloride plating medium was composed of the following: sodium gluconate, 109 mM; potassium gluconate, 5.4 mM; hemi-calcium gluconate, 3.6 mM; magnesium sulfate, 0.8 mM; sodium bicarbonate, 26.2 mM; sodium phosphate monobasic, 1.2 mM; glutamine, 2 mM; glucose, 5 mM; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.3) 10 mM, MEM vitamin solution (10 x concentration of vitamins, Gibco/LifeTechnologies 11120-052) and MEM amino acid solution (1 x concentration of amino acids, Gibco/LifeTechnologies 11130-051).

30

Following overnight incubation in a 5% CO₂ incubator at 37 °C, the cells in the plates were loaded with 20 µl/well of a dye loading solution containing the

commercially available thallium-sensitive fluorescent dye BTC-AM, the acetomethoxy ester of BTC (see US Patent 5,501,980) (2 μ M) and pluronic acid F-127 (Molecular Probes P 6867) (0.02% w/v) in chloride free assay buffer. Chloride free assay buffer was composed of the following: sodium gluconate, 140 mM; 5 potassium gluconate, 2.5 mM; hemi-calcium gluconate, 6 mM; hemi-magnesium gluconate, 2 mM; glucose, 5 mM; HEPES (pH 7.3), 10 mM.

Following incubation in the dye loading solution for from 45-90 min at room temperature, the dye loading solution was removed by aspiration and replaced with 10 40 μ l/well of chloride free assay buffer.

Prior to addition to cell plates, test compound and standard compounds were dissolved in DMSO to 3 mM concentration. Compounds were then diluted from the 3 mM stock to 100-fold over the final assay concentration in DMSO. Finally, 15 compounds in DMSO were diluted from 100-fold over the final assay concentration to 5-fold over the final assay concentration in chloride free assay buffer.

Ten μ l/well of compounds at 5-fold over the final assay concentration were then added to the cell plates. This represents a 1:5 dilution, yielding the final test 20 concentration. The wells used for test compounds were A1-P20. Wells A21-P22 contained a standard opener and a maximally efficacious concentration (positive control). Wells A23-P24 contained chloride free assay buffer containing 1% DMSO (negative control).

25 Following addition of test compounds, the plates were loaded onto the Molecular Devices FLIPR. The 488 nm line of the argon laser was used to excite the BTC and the emission filter was a 540(+/-30) nm. Images were collected at 1Hz. Ten seconds of baseline were collected and then the FLIPR was used to add 13 μ l/well of a stimulus buffer composed of 7.5 mM Ti_2SO_4 in chloride free assay buffer. Images 30 were collected for an additional 60 seconds.

For data analysis, the amplitude of the average of the negative controls was subtracted from all wells. The amplitudes of the test compounds were then compared to the value of four standard deviations of the negative control wells. The lowest concentration of a test compound sufficient to generate a signal amplitude greater than or equal to four standard deviations from the amplitude of the negative controls was defined as the minimal active concentration.

For generating EC_{50} values, compounds were serially diluted in 1:3 volume increments to produce a 10 point concentration series. EC_{50} values were calculated by fitting the resulting amplitudes to a single-site logistic equation. EC_{50} was defined as the concentration of test compound required to yield 50% of the maximal response. Maximal response (Maximal opening) was the largest signal amplitude divided by the negative control amplitude generated by any concentration of a test compound.











Table 1 describes the effect of representative Formula I compounds on KCNQ channels.

Table 1.

Example	Structure	Min. conc. response (μ M)	EC_{50} (μ M)
17		0.3	+++
18		0.3	+++
19		3	+++
20		0.3	+
21		0.3	+++
22		0.3	+++
23		3	++














Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
24		3	++
25		3	+
26		3	++
27		3	+
28		10	+
29		3	++
30		3	++
31		3	+
32		0.3	+++
33		3	++
34		0.3	+++
35		0.3	++
36		10	+
37		3	+
38		30	+
39		10	+
40		30	+
41		10	++
42		10	++












Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
43		3	++
44		3	++
45		3	+
46		10	+
47		3	+
48		3	++
49		0.3	++
50		0.3	++
51		0.3	++
52		3	++
53		3	+
54		0.3	+
55		0.3	+
56		0.3	++
57		0.3	++
58		30	++

Example	Structure	Min. conc. response (μM)	EC ₅₀ (μM)
59		3	++
60		0.3	++
61		30	++
62		3	++
63		30	++
64		10	++
65		10	++
66		3	++
67		30	++
68		30	+

Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
69		3	++
70		3	++
71		30	++
72		3	++
73		0.3	++
74		3	+
75		30	++
76		10	++
77		0.3	+
78		3	++
79		3	++
80		3	+
81		30	++
82		0.3	++
83		0.3	na

Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
84		30	na
85		30	na
86		3	na
87		0.3	na
88		30	na
89		30	na
90		10	na
91		30	na
92		3	na
93		10	na
94		30	na
95		0.3	na
96		3	na
97		10	na
98		3	na
99		3	na
100		30	na

Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
101		3	na
102		0.3	na
103		0.3	na
104		10	na
105		30	na
106		10	na
107		30	na
108		0.3	na
109		3	na
110		3	na
111		0.3	na
112		30	na
113		0.3	na

Example	Structure	Min. conc. response (μ M)	EC ₅₀ (μ M)
114		3	na
115		3	na
116		3	na
117		0.3	na
118		10	na
119		3	na
120		0.3	+++
121		3	+
122		30	na
123		3	na
124		3	na

EC₅₀ values: +++ = <50 nM, ++ = 50-1000 nM, + = 1000-20000 nM.

KCNQ Patch-clamp. Whole-cell patch-clamp recordings were made from an HEK 293 stable cell line expressing mKCNQ2 channels, maintained in culture for 1-

2 days. Patch pipettes had initial resistances of 2.5–4 MΩ. Currents were recorded with an EPC-9 amplifier (HEKA, Lambrecht, Germany) controlled with software (Pulse, HEKA) run on a standard lab PC. Series resistance compensation was used during current recording, and set at 80%. The series resistance (R) and cell capacitance (C) were determined electronically by subtracting the capacitive currents at the onset and offset of a 5mV voltage step. The cancellation of whole-cell capacitive transients was virtually complete in all cells. Analog current signals were low-pass filtered at 2.9kHz using a four-pole Bessel filter (-3dB) and stored on a local network server computer at a sampling rate of 1.5kHz. All recordings were performed at room temperature (20–22°C). The pipette solution contained (mM): KCl, 150; CaCl₂, 2.5; EGTA, 5; MgCl₂, 1; HEPES, 10; pH to 7.3 with KOH, and Osmolality of 290–300 mOsm. The extracellular solution contained (mM): NaCl, 140; KCl, 2.5; CaCl₂, 2.5; MgCl₂, 1; glucose, 10; HEPES, 10; pH to 7.3 with NaOH, and Osmolality of 305–310 mOsm.

For analysis of agents effects on mKCNQ2 currents, the raw current records were displayed on the digital oscilloscope of the Pulse software application. Concentration response data were generated by measuring the difference in the steady-state amplitude of current in the presence of compound at the end of a 600 ms voltage-clamp step from a holding potential of –80mV. The concentration-response data were fitted with Hill-type equations:

$$I = I_{\max} / (1 + EC_{50} / [A]^{nH}),$$

where I is the steady-state current at a given concentration of agonist [A]; and I_{max}, EC₅₀ and nH are parameters estimated from the curve fit. In some cases the concentration-response data were fitted with equations consisting of the sum of two Hill-type components. Current-voltage (I/V) relationships for agonist-evoked currents were obtained by performing 600 ms voltage steps (–110 mV to +40 mV) in the absence and presence of agonist.

Example 21 was verified in a patch-clamp assay measuring the effect of compounds on the current of KCNQ2 channels. The compound exhibited an EC₅₀ of 3.0 nM, demonstrating that this compound opened the KCNQ2 channel.

- 5 *Chung model of neuropathic pain (Chung surgery and von Frey test).* To test agents for activity against peripheral mononeuropathy nerve injury-induced tactile allodynia, male Sprague Dawley rats (wt. 120-160 g) were surgically prepared with unilateral tight ligation of spinal nerves L5 and L6 following the method of Kim and Chung (Kim S.H., Chung J.M. (1992) *Pain*, Sep;50(3):355-63). After 3-4 weeks
10 recovery, paw withdrawal to light touch was assessed as described by Chaplan et al. (Chaplan S.R., et al., (1994) *J. Neurosci Methods*, Jul;53(1):55-63). In brief, rats are placed in a plastic cage with a wire mesh bottom and allowed to acclimate for 15-30 minutes, until cage exploration and grooming stops. The plantar surface of each hind paw is touched with a series of von Frey hairs with varying stiffness requiring a
15 known force to buckle to determine the nociceptive threshold. Adult male Sprague Dawley rats (avg. wt. 340 g) were tested in the present study. After acclimation, baseline von Frey thresholds were assessed for the injured hindpaw at -15 min. Test compounds were delivered at 0 min by the intravenous (i.v.) route in a volume of 0.5-2 ml/kg. The vehicle for test compounds was 100% PEG-400. For gabapentin the
20 vehicle was deionized H₂O. Animals were tested in one of the following 4 treatment conditions: (a) PEG400, (b) gabapentin (Neurontin) 100 mg/kg, (c) test compounds 3 mg/kg and (d) test compounds 10 mg/kg. Following drug administration, von Frey thresholds were measured at 15, 30, 60 and 90 min. Data were analyzed by a 2-way repeated measures analysis of variance followed by Dunnett's test ($p < 0.05$).
25 Experimenters were kept blind to the treatment condition of rats they tested.

Reversal of neuropathic pain behavior may be expressed as a percentage (0-100%) of the maximum possible effect, over and above the vehicle effects. Specifically, drug effects can be described in terms Δ%MPE according to the
30 following equation:

$$\Delta\%MPE = \left(\frac{(AUC_{drug} - AUC_{vehicle})}{((Time \times Max) - AUC_{vehicle})} \right) \times 100$$

where:

AUC_{drug} = area under the curve for von Frey thresholds of the drug-treated group;

AUC_{vehicle} = area under the curve for von Frey thresholds in the vehicle group;

- 5 Time = duration of post-drug testing period (90 min); and Max = maximum von Frey threshold (15 g).

For example, a compound which immediately reversed neuropathic pain behavior to normal levels, such that animals only responded to the highest von Frey filament (15 g), and maintained normal levels through out the post-drug testing period (90 min) would be calculated as $\Delta\%MPE = 100\%$.

The results for example 21 are provided in the following Table 2.

15 Table 2.

Compound	AUC ($\Delta\%MPE$)*
Gabapentin	50 (100 mg/kg, i.v.)
Example 21	28 (10 mg/kg, i.v.)

* $\Delta\%MPE = \%MPE (\text{Drug AUC}) - \%MPE (\text{Vehicle AUC})$

Diabetic model of neuropathic pain (Streptozotocin & von Frey test). To test agents for activity against systemic polyneuropathy nerve injury-induced tactile allodynia, animals were treated with streptozotocin (STZ) to create a diabetic condition by selective cytotoxic action upon pancreatic β -islet cells that produce insulin following the method of Courteix, et al. (Courteix C., et al., (1993) *Pain*, Apr;53(1):81-8). In brief, male Sprague Dawley rats (wt. 200-275 g) received an injection of STZ (75 mg/kg, i.p.) and diabetes was confirmed three weeks after STZ injection by measurement of tail vein blood glucose levels. After 3-4 weeks, paw withdrawal to light touch was assessed as described by Chaplan et al. (Chaplan S.R., et al., (1994) *J Neurosci Methods*, Jul;53(1):55-63). In brief, rats are placed in a plastic cage with a wire mesh bottom and allowed to acclimate for 15-30 minutes, until cage exploration and grooming stops. The plantar surface of each hind paw is

touched with a series of von Frey hairs with varying stiffness requiring a known force to buckle to determine the nociceptive threshold. Adult male Sprague Dawley rats (avg. wt. 300 g) were tested in the present study. After acclimation, baseline von Frey thresholds were assessed for the injured hindpaw at -15 min. All test compounds were delivered at 0 min by the intravenous (i.v.) route in a volume of 0.5-2 ml/kg. The vehicle for the compounds of Formula I was 100% PEG-400. For gabapentin the vehicle was deionized H₂O. Animals were tested in one of the following 4 treatment conditions: (a) PEG400, (b) gabapentin (Neurontin) 200 mg/kg, (c) test compounds 10 mg/kg and (d) test compounds 30 mg/kg. Following drug administration, von Frey thresholds were measured at 15, 30, 60 and 90 min. Data were analyzed by a 2-way repeated measures analysis of variance followed by Dunnett's test ($p < 0.05$). Experimenters were kept blind to the treatment condition of rats they tested.

Reversal of neuropathic pain behavior may be expressed as a percentage (0-100%) of the maximum possible effect, over and above the vehicle effects. Specifically, drug effects can be described in terms $\Delta\%MPE$ according to the following equation:

$$\Delta\%MPE = \left(\frac{(AUC_{drug} - AUC_{vehicle})}{((Time \times Max) - AUC_{vehicle})} \right) \times 100$$

where: AUC_{drug} = area under the curve for von Frey thresholds of the drug-treated group; $AUC_{vehicle}$ = area under the curve for von Frey thresholds in the vehicle group; Time = duration of post-drug testing period (90 min); and Max = maximum von Frey threshold (15 g).

For example, a compound which immediately reversed neuropathic pain behavior to normal levels, such that animals only responded to the highest von Frey filament (15 g), and maintained normal levels through out the post-drug testing period (90 min) would be calculated as $\Delta\%MPE = 100\%$.

The results for example 21 are provided in the following Table 3.

Table 3.

Compound	AUC ($\Delta\%$ MPE)*
Example 21	28 (10 mg/kg, i.v.)

* $\Delta\%$ MPE = $\%$ MPE (Drug AUC) – $\%$ MPE (Vehicle AUC)

5

These results suggest that compounds of Formula I are efficacious in reducing neuropathic pain including pain associated with diabetic neuropathy.

Pharmaceutical composition and methods of treatment

10

Another aspect of this invention includes pharmaceutical compositions comprising at least one compound of Formula I in combination with a pharmaceutical adjuvant, carrier or diluent.

15

A further aspect of this invention relates to a method of treatment or prevention of disorders responsive to opening of KCNQ potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I. The compounds of Formula I should be useful in the treatment of treatment of migraine or a migraine attack, cluster headaches, bipolar disorder, convulsions, mania, acute mania, epilepsy, anxiety, depression, schizophrenia, functional bowel disorders, stroke, traumatic brain injury, multiple sclerosis, neurodegenerative disorders or alleviating pain such as musculoskeletal pain, post operative pain, surgical pain, inflammatory pain, neuropathic pain such as diabetic neuropathy and pain associated with cancer and fibromyalgia.

25

For therapeutic use, the compounds of Formula I will normally be administered as pharmaceutical compositions comprising as an active ingredient at least one compound in association with a pharmaceutically acceptable solid or liquid

carrier and, optionally, with pharmaceutically acceptable adjuncts and excipients employing standard and conventional techniques.

The pharmaceutical compositions include suitable dosage forms for oral,
5 parenteral (including subcutaneous, intramuscular, intradermal and intravenous)
bronchial or nasal administration. If a solid carrier is used, the preparation may be
tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a
troche or lozenge. The solid carrier may contain conventional excipients such as
binding agents, fillers, tableting lubricants, disintegrants, wetting agents and the like.
10 The tablet may, if desired, be film coated by conventional techniques. If a liquid
carrier is employed, the preparation may be in the form of a syrup, emulsion, soft
gelatin capsule, sterile vehicle for injection, an aqueous or non-aqueous liquid
suspension, or may be a dry product for reconstitution with water or other suitable
vehicle before use. Liquid preparations may contain conventional additives such as
15 suspending agents, emulsifying agents, wetting agents, non-aqueous vehicle
(including edible oils), preservatives, as well as flavoring and/or coloring agents. For
parenteral administration, a vehicle normally will comprise sterile water, at least in
large part, although saline solutions, glucose solutions and like may be utilized.
Injectable suspensions also may be used, in which case conventional suspending
20 agents may be employed. Conventional preservatives, buffering agents and the like
also may be added to the parenteral dosage forms. Aerosol compositions can be
formed with pharmaceutically accepted propellants. The pharmaceutical
compositions are prepared by conventional techniques and are normally formulated
in unit doses. The unit dose depends on the composition and can range from about
25 0.01 mg to about 1000 mg. Some unit doses for solid compositions are 1 mg, 10, mg,
100 mg, and 1000 mg. Some unit doses for liquid compositions are 0.01 mg/mL, 0.1
mg/mL, 1 mg/mL, 10 mg/mL, and 100 mg/mL.

A suitable dose of a compound of Formula I or a related pharmaceutical
30 composition for a mammal, including man, is about 0.01 mg/kg to about 100 mg/kg
body weight daily of active ingredient. For parenteral administration, the dose may
be in the range of about 0.1 mg/kg to about 10 mg/kg body weight for intravenous
administration. For oral administration, the dose may be in the range about 0.1

mg/kg to about 100 mg/kg body weight. The active ingredient can be administered continuously or in equal doses from one to four times a day. Usually a small dose is administered, and the dosage is gradually increased until the optimal dosage for the patient is determined. The specific dosing regimen, however, must be carefully
5 monitored and adjusted using sound medical judgement.

DESCRIPTION OF SPECIFIC EMBODIMENTS

Unless otherwise stated, solvents and reagents were used directly as obtained
10 from commercial sources, and reactions were performed under a nitrogen atmosphere. Flash chromatography was conducted on Silica gel 60 (0.040-0.063 particle size; EM Science supply). ¹H NMR spectra were recorded on a Bruker DRX-500f at 500 MHz; a Bruker DPX-300B at 300 MHz; or a Varian Gemini 300 at 300 MHz. The chemical shifts were reported in ppm on the δ scale relative to δ TMS =
15 0. The following internal references were used for the residual protons in the following solvents: CDCl₃ (δ_H 7.26), CD₃OD (δ_H 3.30) and DMSO-*d*₆ (δ_H 2.50). Standard acronyms were employed to describe the multiplicity patterns: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad), app (apparent). The coupling constant (*J*) is in hertz. LC/MS was performed on a
20 Shimadzu LC-10AS liquid chromatograph using a SPD-10AV UV-VIS detector with Mass Spectrometry data determined using a Micromass LC Platform in positive electrospray ionization mode (ESI+). Mass Spectrometry (MS) data was obtained using a standard flow injection technique on a Micromass LC Platform in positive electrospray ionization mode (ESI+) unless otherwise noted. High resolution mass
25 spectrometry (HRMS) data was obtained using a standard flow injection technique on a Finnigan MAT 900 mass spectrometer in electrospray ionization (ESI) mode. The analytical reverse phase HPLC methods are as follows unless otherwise noted. A run of x minutes is a gradient of x-1 minutes from 100%A to 100%B followed by a 1 min at 100%B. For example, a 3 min run is 2 min gradient from 100%A to 100%B
30 followed by 1 min at 100%B. Solvent A: 10% MeOH/90% H₂O/0.1 % TFA; solvent B: 90% MeOH/10% H₂O/0.1 % TFA; Column 1: YMC ODS-A 3.0 x 50 mm S7 C18; column 2: XTERRA 3.0 x 50 mm S7; column 3: YMC ODS-A C18 S5 4.6 x 33 mm; column 4: XTERRA C18 S5 4.6 x 50 mm; column 5 YMC C18 S5 4.6 x 50 mm.

Preparative reverse phase HPLC was performed on a Shimadzu LC-8A automated preparative HPLC system with detector (SPD-10AV UV-VIS) wavelength and solvent systems (A and B) the same as above except where otherwise noted.

5

EXAMPLE 1

2-Amino-4-Trifluoromethyl-thiazole-5-carboxylic acid ethyl ester. To a solution of ethyl 2-chloro-4,4,4-trifluoroacetoacetate (50.0 g, 230 mmol) in ethanol (250 mL) was added thiourea (17.5 g, 230 mmol). The resulting mixture was heated at reflux
10 for 3 h, at which time TLC indicated a complete reaction. The mixture was concentrated *in vacuo*, and the residue dissolved in ether. The organic layer was successively washed with aqueous sodium bicarbonate, and brine, then dried over magnesium sulfate and concentrated *in vacuo*. The resulting solid was recrystallized with ethyl acetate and hexanes to give white crystals (41.64 g, 75% yield). ¹H NMR
15 (MeOD-d₄, 300MHz): δ 4.26 (q, $J = 7.1$ Hz, 2H), 1.31 (t, $J = 7.1$ Hz, 3H).

EXAMPLE 2

2-Bromo-4-Trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (III). To a solution of the aminothiazole (40.0 g, 167 mmol) in 48% HBr (300 mL) at 0 °C was
20 added a 0 °C solution of sodium nitrite (17.0 g, 250 mmol) in water (200 mL) dropwise over 1 h. The mixture was stirred at 0 °C for an additional 0.5 h, at which time a 0 °C solution of CuBr (23.9 g, 167 mmol) in 48% HBr (200 mL) over 0.5 h. The mixture was stirred for an additional 0.5 h at 0 °C, then for 2 h at room temperature. The mixture was then extracted three times with methylene chloride.
25 The combined organic extracts were then dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The product was purified by chromatography (SiO₂, Hexane to 2.5 % EtOAc/Hexane) to yield pure IV (47.0 g, 93 % yield). ¹H NMR (CDCl₃, 300MHz): δ 4.40 (q, $J = 7.1$ Hz, 2H), 1.38 (t, $J = 7.1$ Hz, 3H).

EXAMPLE 3Preparation of Formula II compounds

5 **2-Phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester.** To a solution of thiazole **III** (2.0 g, 6.6 mmol) and the phenyl boronic acid (9.9 mmol) in THF (10 mL) was added potassium fluoride (1.15 g, 19.8 mmol), palladium (II) acetate (74 mg, 0.33 mmol), and 2-(di-*t*-butylphosphino)biphenyl (197 mg, 0.66 mmol). This mixture was stirred at 25 °C for 24 h. Diethyl ether (100 mL) was then added and the mixture was washed with 1 N aqueous NaOH (2 x 50 mL), saturated aqueous NaCl (1 x 50 mL), dried over MgSO₄ and concentrated *in vacuo* to give an off-white solid. Purification by flash chromatography (silica, 0-2.5% ethyl acetate/hexane) gave the product, generally in 60-90% yield.

EXAMPLE 4Preparation of IIb

15 To a solution of 2-(2-methoxy)phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (3.78 mmol) in CH₂Cl₂ (17.7 mL) at -78 °C under a Nitrogen atmosphere was added 1M BBr₃ in CH₂Cl₂ (4.75 mL, 4.75 mmol, 1.25 eq). The resulting mixture was stirred for 2 h at 0 °C, at which time TLC indicated the consumption of starting material. The solution was cooled to -78 °C and quenched with saturated NaHCO₃ solution. The mixture was brought to room temperature, and extracted three times with CH₂Cl₂. The combined organic phases were dried over MgSO₄ and concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel (10% EtOAc/Hexane). Yield: 900 mg (75%).

EXAMPLE 5Preparation of IIc

30 To a solution of 2-(2-hydroxy)phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (3.15 mmol) in DMF (30.0 mL) at ambient temperature under a Nitrogen atmosphere was added 1,2-dibromoethane (5.43 mL, 63 mmol, 20 eq), then excess

NaH. The resulting mixture was stirred for 18 h, at which time HPLC indicated the consumption of starting material. The solution was carefully quenched with ethanol, followed by saturated NH_4Cl solution. The solution was extracted three times with EtOAc, the combined organic phases were dried over MgSO_4 and concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel. Yield: 950 mg (71%).

EXAMPLE 6

Preparation of II_d

To a solution of 2-[2-(2-bromoethoxy)]phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (826 μmol) in acetone (3.5 mL) at ambient temperature under a Nitrogen atmosphere was added the appropriate secondary amine (4.13 mmol, 5 eq), then catalytic NaI (31 mg, 207 μmol , 0.2 eq). The resulting mixture was heated to 80 °C and stirred for 18 h, at which time HPLC indicated the consumption of starting material. The solution was concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel (CH_2Cl_2 , followed by 5% MeOH/ CH_2Cl_2). Yield: 320 mg (93%).

EXAMPLE 7

Preparation of II_e

To a suspension of 2-(2-hydroxy)phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (3.15 mmol) in CH_2Cl_2 (10.0 mL) at 0 °C under a Nitrogen atmosphere was added pyridine (1.28 mL, 15.8 mmol, 5 eq), at which time the mixture was a homogeneous solution. Triflic anhydride (610 μL , 3.63 mmol, 1.15 eq) was added dropwise, and the reaction was stirred for 0.5 h, at which time TLC indicated the consumption of starting material. The solution was quenched with saturated NH_4Cl solution. The solution was extracted three times with CH_2Cl_2 , the combined organic phases were dried over MgSO_4 and concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel (10% EtOAc/Hexane). Yield: 601.9 mg (42%).

EXAMPLE 8Preparation of II_f

To mixture of 2-(2-trifluoromethylsulfonyl)phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (557 μ mol), Cs₂CO₃ (510 mg, 1.56 mmol, 2.8 eq), Pd(OAc)₂ (7.5 mg, 33 μ mol, 0.06 eq), and BINAP (31.3 mg, 50 μ mol, 0.09 eq) in a sealed tube was added toluene (10.0 mL), followed by morpholine (117 μ L, 1.34 mmol, 2.4 eq). The mixture was flushed with Nitrogen, and heated at 90 °C for 24 h. The solvent was removed *in vacuo* and the crude product was used directly for subsequent chemistry.

EXAMPLE 9Preparation of II_g

A solution of stannane VI (3.8 g, 12.1 mmol, 2 eq) and bromide III (1.83 g, 6.0 mmol, 1 eq) in DMF (17.2 mL) was sparged with Nitrogen. Solid Pd(PPh₃)₂Cl₂ (217 mg, 309 μ mol, 0.052 eq) and CuI (92 mg, 483 μ mol, 0.081 eq) were added, and the reaction was heated at 60 °C in a sealed tube for 18 h. The reaction was cooled to ambient temperature, and was diluted with water. The mixture was extracted two times into EtOAc, and the combined organic layers were washed with saturated NaCl solution. The EtOAc solution was further dried over MgSO₄, and concentrated *in vacuo*. Purification by silica gel chromatography (25% EtOAc/Hexane) provided the pure product. Yield: 1.97 g, (88%).

EXAMPLE 10Preparation of II_i

To a solution of cinnamate ester III_h (3.18 g, 8.26 mmol, 1 eq) in ether (26 mL) was added a solution of sodium periodate (3.83 g, 17.9 mmol, 2.17 eq) in water (26 mL). A 2.5 wt % solution of OsO₄ in *t*-BuOH (5.6 mL, 427 μ mol, 0.052 eq) was then added. The resulting mixture was vigorously stirred at ambient temperature for 24 h.

The reaction was filtered through a pad of silica gel and then was concentrated *in vacuo* to afford the brown aldehyde **III**. Quantitative yield.

EXAMPLE 11

5

Preparation of V

To a solution of 2-bromobenzaldehyde (5.30 mmol) in benzene (40 mL) was added ethylene glycol (1.26 mL, 22.6 mmol, 4.3 eq) and *p*-toluenesulfonic acid (70 mg, 0.37 mmol, 0.07 eq). The resulting mixture was heated at reflux in a Dean-Stark
10 apparatus. After 4 h, the reaction was cooled to ambient temperature, quenched with triethylamine, and concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel. Quantitative yield.

EXAMPLE 12

15

Preparation of VI

To a solution of 2-dioxolanyl bromobenzene (13.0 mmol) in THF (22.5 mL) at -78 °C under Nitrogen was added 2.5 M *n*-BuLi in hexane (5.73 mL, 14.3 mmol, 1.1 eq) dropwise. After 1 h, a 1 M solution of Me₃SnCl in THF (14.4 mL, 14.4 mmol, 1.1
20 eq) was added. After 15 minutes, the temperature bath was removed, and the reaction was allowed to reach ambient temperature. Ether was added, followed by water. The mixture was extracted two times into ether, and the combined organic layers were washed with saturated NaCl solution. The ether solution was further dried over MgSO₄, and concentrated *in vacuo*. ¹H NMR revealed ~90% conversion
25 to the desired stannane, which was used as-is in subsequent chemistry. Mass yield: 3.8 g, (92%).

Preparation of Formula I compounds

Examples of ester hydrolysis procedure

5

EXAMPLE 13

10 **2-Phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid.** To a solution of 2-phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester (1.6 g, 5.3 mmol) in THF (16 mL) was added 1 N aqueous LiOH (16 mL, 16 mmol). This mixture was brought to reflux and stirred vigorously for 1 h. The mixture was allowed to cool to 25 °C and 1 N aqueous HCl (35 mL, 35 mmol) was added. The mixture was extracted with ethyl acetate (2 x 50 mL) and the combined organic extracts were washed with saturated aqueous NaCl (1 x 50 mL), dried over MgSO₄ and concentrated *in vacuo* to give the carboxylic acid as a white solid (1.32 g, 91%).

15

Examples of carboxylic acid amination procedures

EXAMPLE 14

20 **2-Phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid [1-(3-trifluoromethoxy-phenyl)-ethyl]-amide.** To a solution of 2-phenyl-4-trifluoromethyl-thiazole-5-carboxylic acid (35 mg, 0.128 mmol) in DMF (1 mL) was added PyBOP (73 mg, 0.141 mmol) and DMAP (16 mg, 0.128 mmol). A solution of 1-(3-trifluoromethoxy-phenyl)-ethylamine (27 mg, 0.128 mmol) in DMF (0.5 mL) was then added, followed
25 by Et₃N (36 µL, 0.256 mmol). This mixture was stirred at 25 °C for 18 h. The reaction mixture was applied directly to a preparatory HPLC column for purification (C18, 10-100% methanol/water/0.1% trifluoroacetic acid) which gave the amide as a white solid (24.9 mg, 42%).

EXAMPLE 15**Preparation of Id**

To a solution of acetal **Ic** (224 μmol) in 9:1 acetone:water (6 mL) was added *p*-toluenesulfonic acid (20 mg, 105 μmol , 0.47 eq). The resulting mixture was heated to 60 °C. After 16 h, the reaction was cooled to ambient temperature, quenched with saturated NaHCO_3 solution, and extracted three times into EtOAc. The combined organic phases were dried over MgSO_4 and concentrated *in vacuo*. Purification was accomplished with chromatography on silica gel. Quantitative yield.

10

EXAMPLE 16**Preparation of Ie**

To a suspension of aldehyde **Id** (91.1 μmol) in ethylene glycol dimethyl ether (400 μL) was added the appropriate amine (230 μmol , 2.5 eq), trimethyl orthoformate (33 μL , 300 μmol , 3.3 eq), and acetic acid (2 μL , 35 μmol , 0.38 eq). The resulting mixture was stirred at ambient temperature for 24 h. Solid $\text{NaBH}(\text{OAc})_3$ was then added, and stirring was continued for another 16 h. The reaction was diluted with methanol and loaded onto a strong-cation ion exchange column (SCX). The column was washed with methanol (20 mL), then the desired product was eluted with 2 M NH_3/MeOH (15 mL). The ammonia solution was concentrated *in vacuo* to afford the pure products.

20

All examples were made using these methods. Compounds which needed further purification were purified by flash chromatography (silica, 0-10% methanol/chloroform).

25

EXAMPLE 17

2-(4-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 7.96-7.92 (m, 2H), 7.41-7.32(m, 2H), 7.21-7.13 (m, 4H), 6.45 (br d, J = 6.6 Hz, 1H), 5.27 (app quint, J =

30

7.0 Hz, 1H), 1.61 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 478, RT = 1.833 (column 1; run time: 3 min).

EXAMPLE 18

5

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.43-8.40 (m, 1H), 7.47-7.03 (m, 7H), 6.43 (app br d, 1H), 5.30 (app quint, $J = 7.0$ Hz, 1H), 4.05 (s, 3H), 1.61 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 490, RT = 1.850 (column 5; run time: 3 min).

10

EXAMPLE 19

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.43-8.40 (m, 1H), 7.63 – 7.44 (m, 5H), 7.13-7.03 (m, 2H), 6.45 (br d, 1H), 5.33 (app quint, $J = 7.0$ Hz, 1H), 4.05 (s, 3H), 1.63 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 474, RT = 1.800 (column 5; run time: 3 min).

15

20

EXAMPLE 20

2-(3,4-dioxolanylphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 7.47-7.38 (m, 3H), 7.30 (d, $J = 7.7$ Hz, 1H), 7.17 (m, 2H), 6.87 (d, $J = 7.7$ Hz, 1H), 6.43 (br d, $J = 5.9$ Hz, 1H), 6.05 (s, 2H), 5.27 (app quint, $J = 7.0$ Hz, 1H), 1.60 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 504, RT = 1.817 (column 1; run time: 3 min).

25

EXAMPLE 21

30

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.35-8.30 (m, 1H), 7.48-7.27 (m, 4H), 7.24-7.18 (m, 3H), 6.43 (br d, $J = 5.9$ Hz, 1H), 5.30 (app quint, $J = 7.0$ Hz, 1H), 1.62 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 478, RT = 1.833 (column 5; run time: 3 min).

35

EXAMPLE 22

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.33 (dd, *J* = 1.8, 7.7 Hz, 1H), 7.62-7.45 (m, 5H), 7.33-7.28 (m, 1H), 7.25-7.18 (m, 1H), 6.45 (app br d, 1H), 5.33 (app quint, *J* = 7.0 Hz, 1H), 1.64 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 462, RT = 1.797 (column 5; run time: 3 min).

EXAMPLE 23

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(1-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.42-8.39 (m, 1H), 7.49 – 7.44 (m, 1H), 7.29 (m, 1H), 7.12-7.03 (m, 2H), 6.93-6.83 (m, 3H), 6.42 (br d, *J* = 6.2 Hz, 1H), 5.24 (app quint, *J* = 7.0 Hz, 1H), 4.04 (s, 3H), 3.86 (t, *J* = 4.7 Hz, 4H), 3.18 (t, *J* = 4.7 Hz, 4H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 491, RT = 1.537 (column 1; run time: 3 min).

EXAMPLE 24

2-(3-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 7.49-7.32 (m, 5H), 7.21 – 7.05 (m, 3H), 6.46 (br d, *J* = 6.2 Hz, 1H), 5.28 (app quint, *J* = 7.0 Hz, 1H), 3.88 (s, 3H), 1.61 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 490, RT = 1.867 (column 1; run time: 3 min).

EXAMPLE 25

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.42 (dd, *J* = 1.5, 7.7 Hz, 1H), 7.47 – 7.44 (m, 1H), 7.27-7.22 (m, 1H), 7.13–7.03 (m, 2H), 6.74 (m, 3H), 6.41 (app br d, 1H), 5.23 (app quint, *J* = 7.0 Hz, 1H), 4.05 (s, 3H), 2.97 (s, 6H), 1.62 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 449, RT = 1.360 (column 5; run time: 3 min).

EXAMPLE 26

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.31 (td, *J* = 1.8, 7.7 Hz, 1H), 7.55-7.45 (m, 1H), 7.31-7.21 (m, 3H), 6.73 (m, 3H), 6.45 (br d, *J* = 6.2 Hz, 1H), 5.25 (app quint, *J* = 7.0 Hz, 1H), 2.97 (s, 6H), 1.61 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 437, RT = 1.287 (column 5; run time: 3 min).

EXAMPLE 27

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-(3-fluorophenyl)methyl-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.42 (dd, *J* = 1.8, 8.1 Hz, 1H), 7.47-7.44 (m, 1H), 7.34 (m, 1H), 7.14-6.97 (m, 5H), 6.73 (m, 3H), 6.53 (br s, 1H), 4.64 (d, *J* = 5.9 Hz, 2H), 4.06 (s, 3H); LCMS (M+) 410, RT = 1.697 (column 5; run time: 3 min).

EXAMPLE 28

2-(4-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 7.88 (dt, *J* = 2.4, 9.5 Hz, 2H), 7.44-7.37 (m, 1H), 7.34-7.27 (m, 1H), 7.23-7.12 (m, 2H), 6.97 (dt, *J* = 2.3, 9.4 Hz, 2H), 6.42 (br d, *J* = 6.6 Hz, 1H), 5.27 (app quint, *J* = 7.0 Hz, 1H), 3.87 (s, 3H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 490, RT = 1.863 (column 5; run time: 3 min).

EXAMPLE 29

2-(3,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 7.49-7.26 (m, 4H), 7.17 (m, 2H), 6.90 (d, *J* = 8.1 Hz, 1H), 6.43 (br d, *J* = 7.0 Hz, 1H), 5.28 (app quint, *J* = 7.0 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H), 1.61 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 520, RT = 1.813 (column 1; run time: 3 min).

EXAMPLE 30

2-(2,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.31 (d, *J* = 8.8 Hz, 1H), 7.42-7.13 (m, 4H), 6.62 (dd, *J* = 2.3, 8.8 Hz, 1H), 6.52 (d, *J* = 2.3 Hz, 1H), 6.45 (br d, *J* = 6.6 Hz, 1H), 5.28 (app quint, *J* = 7.0 Hz, 1H), 4.00 (s, 3H), 3.87 (s, 3H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M⁺) 520, RT = 1.873 (column 1; run time: 3 min).

10

EXAMPLE 31

2-(2,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 500 MHz): δ 8.32 (d, *J* = 8.8 Hz, 1H), 7.30-7.24 (m, 1H), 6.93-6.83 (m, 3H), 6.62 (dd, *J* = 2.4, 8.8 Hz, 1H), 6.53 (d, *J* = 2.4 Hz, 1H), 6.42 (br d, *J* = 7.0 Hz, 1H), 5.24 (app quint, *J* = 7.0 Hz, 1H), 4.01 (s, 3H), 3.87 (s, 3H), 3.86 (t, *J* = 4.9 Hz, 4H), 3.18 (t, *J* = 4.9 Hz, 4H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M⁺) 521, RT = 1.607 (column 1; run time: 3 min).

20

EXAMPLE 32

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(1-piperidinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.42 (dd, *J* = 1.5, 7.7 Hz, 1H), 7.49-7.44 (m, 1H), 7.28-7.23 (m, 1H), 7.13-7.03 (m, 2H), 6.95-6.80 (m, 3H), 6.40 (app br d, 1H), 5.24 (app quint, *J* = 7.0 Hz, 1H), 4.05 (s, 3H), 3.18 (t, *J* = 5.1 Hz, 4H), 1.72 (t, *J* = 5.1 Hz, 4H), 1.60 (d, *J* = 7.0 Hz, 3H), 1.56 (s, 2H); LCMS (M⁺) 489, RT = 1.427 (column 1; run time: 3 min).

30

EXAMPLE 33

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(1-pyrrolidinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.41 (dd, *J* = 1.2, 7.8 Hz,

1H), 7.48-7.02 (m, 4H), 6.66 (d, $J = 7.4$ Hz, 1H), 6.52 (m, 3H), 5.25 (app quint, $J = 6.8$ Hz, 1H), 4.03 (s, 3H), 3.29 (t, $J = 6.2$ Hz, 4H), 2.01 (t, $J = 6.2$ Hz, 4H), 1.60 (d, $J = 6.8$ Hz, 3H); LCMS (M+) 475, RT = 1.593 (column 1; run time: 3 min).

5

EXAMPLE 34

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl₃, 300 MHz): δ 8.41 (dd, $J = 1.8, 8.1$ Hz, 1H), 7.45-7.02 (m, 5H), 6.82-6.74 (m, 3H), 6.45 (br d, $J = 7.1$ Hz, 1H), 6.28 (m, 1H), 6.16 (br d, $J = 3.1$ Hz, 1H), 5.23 (app quint, $J = 7.0$ Hz, 1H), 4.46 (s, 2H), 4.03 (s, 3H), 3.01 (s, 3H), 1.61 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 515, RT = 1.570 (column 1; run time: 3 min).

15

EXAMPLE 35

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl₃, 300 MHz): δ 8.31 (td, $J = 1.8, 7.7$ Hz, 1H), 7.46-7.21 (m, 5H), 6.80-6.72 (m, 3H), 6.46 (br d, $J = 7.0$ Hz, 1H), 6.28 (dd, $J = 2.0, 3.1$ Hz, 1H), 6.14 (br d, $J = 2.6$ Hz, 1H), 5.22 (app quint, $J = 7.0$ Hz, 1H), 4.46 (s, 2H), 3.01 (s, 3H), 1.61 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 503, RT = 1.560 (column 1; run time: 3 min).

20

EXAMPLE 36

2-(3,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-[(1-pyrrolidinyl)methyl]phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl₃, 500 MHz): δ 7.47-7.23 (m, 5H), 6.88 (d, $J = 8.4$ Hz, 1H), 6.52 (br d, $J = 7.3$ Hz, 1H), 5.25 (app quint, $J = 7.1$ Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.63 (m, 2H), 2.52 (br s, 4H), 1.79 (t, $J = 6.6$ Hz, 4H), 1.60 (d, $J = 6.9$ Hz, 3H); LCMS (M+) 519, RT = (column 1; run time: 3 min).

30

EXAMPLE 37

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-[(4-morpholinyl)methyl]phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 400 MHz): δ 8.31 (m, 1H), 7.47 (m, 1H), 7.34-7.21 (m, 5H), 6.51 (br d, *J* = 7.0, 1H), 5.27 (app quint, *J* = 7.1 Hz, 1H), 3.71 (t, *J* = 4.6 Hz, 4H), 3.50 (s, 2H), 2.44 (t, *J* = 4.3 Hz, 4H), 1.61 (d, *J* = 6.9 Hz, 3H); LCMS (M⁺) 493, RT = 1.407 (column 1; run time: 3 min).

10

EXAMPLE 38

2-(1-naphthyl)-4-(trifluoromethyl)-N-[1-[3-[(diethylamino)methyl]phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.72 (d, *J* = 8.4 Hz, 1H), 8.00-7.24 (m, 9H), 6.61 (br d, *J* = 7.1, 1H), 5.30 (app quint, *J* = 7.1 Hz, 1H), 3.59 (s, 2H), 2.54 (q, *J* = 7.1 Hz, 1H), 1.64 (d, *J* = 6.9 Hz, 3H), 1.06 (t, *J* = 7.1 Hz, 6H); LCMS (M⁺) 511, RT = 1.557 (column 1; run time: 3 min).

EXAMPLE 39

20 2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-(3-aminophenyl)ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.40 (dd, *J* = 1.8, 8.1 Hz, 1H), 7.45 (ddd, *J* = 1.8, 7.2, 8.5 Hz, 1H), 7.16-7.02 (m, 3H), 6.80-6.67 (m, 3H), 6.38 (br d, *J* = 7.3 Hz, 1H), 5.18 (app quint, *J* = 7.1 Hz, 1H), 4.03 (s, 3H), 1.57 (d, *J* = 6.9 Hz, 3H); LCMS (M⁺) 421, RT = 1.230 (column 1; run time: 3 min).

25

EXAMPLE 40

2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(guanidiny]phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (MeOD, 300 MHz): δ 8.36 (dd, *J* = 1.5, 8.1 Hz, 1H), 7.54-7.13 (m, 7H), 5.16 (app quint, *J* = 7.1 Hz, 1H), 4.10 (s, 3H), 1.56 (d, *J* = 6.9 Hz, 3H); LCMS (M⁺) 463, RT = 1.263 (column 1; run time: 3 min).

30

EXAMPLE 41

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.12 (dd, *J* = 3.1, 9.2 Hz, 1H), 7.43-7.13 (m, 5H), 6.99 (dd, *J* = 4.2, 9.1 Hz, 1H), 6.44 (br d, *J* = 6.9 Hz, 1H), 5.29 (app quint, *J* = 7.1 Hz, 1H), 4.03 (s, 3H), 1.61 (d, *J* = 6.9 Hz, 3H); LCMS (M+) 508, RT = 2.723 (column 3; run time: 4 min).

EXAMPLE 42

10

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.12 (dd, *J* = 3.2, 9.2 Hz, 1H), 7.27-6.69 (m, 6H), 6.45 (br d, *J* = 6.7 Hz, 1H), 5.25 (app quint, *J* = 7.1 Hz, 1H), 4.03 (s, 3H), 2.97 (s, 6H), 1.62 (d, *J* = 6.9 Hz, 3H); LCMS (M+) 467, RT = 2.103 (column 3; run time: 4 min).

EXAMPLE 43

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.13 (dd, *J* = 2.9, 9.2 Hz, 1H), 7.62-7.50 (m, 4H), 7.20-6.97 (m, 2H), 6.45 (br d, *J* = 7.3 Hz, 1H), 5.33 (app quint, *J* = 6.9 Hz, 1H), 4.04 (s, 3H), 1.63 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 492, RT = 2.680 (column 3; run time: 4 min).

25

EXAMPLE 44

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[(3-fluorophenyl)methyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.14 (dd, *J* = 3.2, 9.3 Hz, 1H), 7.36-6.98 (m, 6H), 6.45 (app br s, 1H), 4.65 (d, *J* = 5.8 Hz, 2H), 4.05 (s, 3H); LCMS (M+) 428, RT = 2.557 (column 3; run time: 4 min).

30

EXAMPLE 45

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[(3-methoxyphenyl)methyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.13 (dd, *J* = 3.3, 9.2 Hz, 1H), 7.32-6.84 (m, 6H), 6.45 (app br s, 1H), 4.63 (d, *J* = 5.6 Hz, 2H), 4.05 (s, 3H), 3.82 (s, 3H); LCMS (M⁺) 440, RT = 20.547 (column 3; run time: 4 min).

EXAMPLE 46

10

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[(3-trifluoromethoxyphenyl)methyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.13 (dd, *J* = 3.3, 9.2 Hz, 1H), 7.44-6.98 (m, 6H), 6.52 (app br s, 1H), 4.68 (d, *J* = 5.9 Hz, 2H), 4.05 (s, 3H); LCMS (M⁺) 494, RT = 2.713 (column 3; run time: 4 min).

EXAMPLE 47

(S)-2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.10 (dd, *J* = 2.9, 9.2 Hz, 1H), 7.46-6.96 (m, 6H), 6.67 (br d, *J* = 6.9 Hz, 1H), 5.27 (app quint, *J* = 7.0 Hz, 1H), 4.07-3.98 (m, 5H), 3.42 (t, *J* = 4.8 Hz, 4H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M⁺) 509, RT = 2.383 (column 3; run time: 4 min).

25

EXAMPLE 48

(S)-2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(methoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.13 (dd, *J* = 3.2, 9.3 Hz, 1H), 7.33-6.83 (m, 6H), 6.38 (br d, *J* = 6.6 Hz, 1H), 5.32-5.20 (m, 1H), 4.04 (s, 3H), 3.82 (s, 3H), 1.61 (d, *J* = 6.9 Hz, 3H); LCMS (M⁺) 454, RT = 2.560 (column 3; run time: 4 min).

30

EXAMPLE 49

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.38-8.31 (m, 1H), 7.54-7.18 (m, 7H), 6.40 (app br s, 1H), 5.31 (app quint, *J* = 7.1 Hz, 1H), 1.62 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 494, RT = 2.733 (column 3; run time: 4 min).

EXAMPLE 50

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 500 MHz): δ 8.35-8.31 (m, 1H), 7.53-7.49 (m, 1H), 7.44-7.38 (m, 2H), 7.27-7.22 (m, 1H), 6.74-6.65 (m, 3H), 6.47 (br d, *J* = 6.7 Hz, 1H), 5.23 (app quint, *J* = 7.0 Hz, 1H), 2.97 (s, 6H), 1.62 (d, *J* = 6.8 Hz, 3H); LCMS (M+) 453, RT = 2.077 (column 3; run time: 4 min).

EXAMPLE 51

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.38-8.31 (m, 1H), 7.62-7.39 (m, 7H), 6.44 (br d, *J* = 6.0 Hz, 1H), 5.34 (app quint, *J* = 6.9 Hz, 1H), 1.64 (d, *J* = 7.0 Hz, 3H); LCMS (M+) 478, RT = 2.687 (column 3; run time: 4 min).

EXAMPLE 52

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 500 MHz): δ 8.36-8.30 (m, 1H), 7.52-7.26 (m, 4H), 6.92-6.84 (m, 3H), 6.45 (br d, *J* = 7.0 Hz, 1H), 5.24 (app quint, *J* = 7.0 Hz, 1H), 3.86 (t, *J* = 4.8 Hz, 4H), 3.18 (t, *J* = 4.8 Hz, 4H), 1.61 (d, *J* = 6.9 Hz, 3H); LCMS (M+) 495, RT = 2.397 (column 3; run time: 4 min).

EXAMPLE 53

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 400 MHz): δ 8.36-8.31 (m, 1H), 7.51-7.26 (m, 7H), 6.45 (br d, *J* = 6.8 Hz, 1H), 5.28 (app quint, *J* = 7.1 Hz, 1H), 3.71 (t, *J* = 4.5 Hz, 4H), 3.51 (s, 2H), 2.44 (t, *J* = 4.5 Hz, 4H), 1.62 (d, *J* = 6.9 Hz, 3H); LCMS (M⁺) 509, RT = 2.093 (column 3; run time: 4 min).

10

EXAMPLE 54

2-[2-(2-diethylaminoethyl)phenyl]-4-(trifluoromethyl)-N-(3-fluorobenzyl)-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.42 (m, 1H), 7.46-7.30 (m, 2H), 7.15-7.01 (m, 5H), 6.48 (app br s, 1H), 4.65 (d, *J* = 5.6 Hz, 2H), 4.30 (t, *J* = 6.6 Hz, 2H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.65 (q, *J* = 7.3 Hz, 4H), 1.07 (t, *J* = 7.3 Hz, 6H); LCMS (M⁺) 495, RT = 1.420 (column 3; run time: 3 min).

EXAMPLE 55

20 2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(methoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.39 (m, 1H), 7.48-7.27 (m, 4H), 6.98-6.83 (m, 3H), 6.41 (br d, *J* = 6.2 Hz, 1H), 5.25 (app quint, *J* = 7.0 Hz, 1H), 3.97 (t, *J* = 4.5 Hz, 4H), 3.82 (s, 3H), 2.97 (t, *J* = 4.5 Hz, 4H), 1.60 (d, *J* = 7.0 Hz, 3H); LCMS (M⁺) 491, RT = 2.447 (column 3; run time: 4 min).

25

EXAMPLE 56

2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.40 (m, 1H), 7.63-7.31 (m, 7H), 6.46 (br d, 1H), 5.33 (app quint, *J* = 7.0

30

Hz, 1H), 3.98 (t, $J = 4.4$ Hz, 4H), 2.97 (t, $J = 4.4$ Hz, 4H), 1.63 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 529, RT = 2.593 (column 3; run time: 4 min).

EXAMPLE 57

5

2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.40 (m, 1H), 7.49-7.18 (m, 7H), 6.44 (br s, 1H), 5.30 (app quint, $J = 7.0$ Hz, 1H), 3.98 (t, $J = 4.4$ Hz, 4H), 2.97 (t, $J = 4.4$ Hz, 4H), 1.61 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 545, RT = 2.667 (column 3; run time: 4 min).

EXAMPLE 58

2-[4-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 7.83 (m, 2H), 7.43-7.29 (m, 2H), 7.21-7.14 (m, 2H), 6.94-6.85 (m, 2H), 6.42 (br d, 1H), 5.27 (app quint, $J = 7.0$ Hz, 1H), 3.87 (t, $J = 4.8$ Hz, 4H), 3.28 (t, $J = 4.8$ Hz, 4H), 1.60 (d, $J = 7.0$ Hz, 3H); LCMS (M+) 545, RT = 1.973 (column 3; run time: 3 min).

20

EXAMPLE 59

2-[3-[(4-pyridinyl)ethylaminomethyl]phenyl]-4-(trifluoromethyl)-N-(3-trifluoromethoxybenzyl)-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 8.37 (s, 2H), 7.61-7.08 (m, 11H), 4.66 (d, $J = 5.5$ Hz, 2H), 3.91 (s, 2H), 3.50 (s, 2H), 2.45 (q, $J = 7.0$ Hz, 2H), 0.94 (t, $J = 7.0$ Hz, 3H); LCMS (M+) 594, RT = 1.937 (column 2; run time: 4 min).

25

EXAMPLE 60

30

(S)-2-[3-[(4-pyridinyl)ethylaminomethyl]phenyl]-4-(trifluoromethyl)-N-[1-(3-methoxyphenyl)ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ

8.45-8.40 (m, 2H), 7.58-6.92 (m, 10H), 6.54 (br d, $J = 6.7$ Hz, 1H), 5.25 (app quint, $J = 7.0$ Hz, 1H), 3.82 (s, 3H), 3.52 (s, 2H), 3.48 (s, 2H), 2.46 (q, $J = 7.0$ Hz, 2H), 1.61 (d, $J = 7.0$ Hz, 3H), 0.96 (t, $J = 7.0$ Hz, 3H); LCMS (M^+) 554, RT = 1.627 (column 2; run time: 4 min).

5

EXAMPLE 61

2-[3-(diethylaminomethyl)pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.46 (d, $J = 5.5$ Hz, 1H), 8.20 (d, $J = 7.7$ Hz, 1H), 7.44-7.10 (m, 5H), 6.32 (br d, $J = 5.9$ Hz, 1H), 5.29 (app quint, $J = 7.2$ Hz, 1H), 4.17 (s, 2H), 2.58 (q, $J = 7.2$ Hz, 4H), 1.60 (d, $J = 7.0$ Hz, 3H), 1.02 (t, $J = 7.2$ Hz, 6H); LCMS (M^+) 546, RT = 1.670 (column 3; run time: 4 min).

15

EXAMPLE 62

(S)-2-[3-(pyridin-4-ylmethyl)ethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.56-8.41 (m, 3H), 8.19 (d, $J = 7.7$ Hz, 1H), 7.43-7.33 (m, 1H), 7.33-7.18 (m, 3H), 6.97-6.79 (m, 3H), 6.34 (br d, $J = 8.1$ Hz, 1H), 5.23 (app quint, $J = 7.2$ Hz, 1H), 4.24 (s, 2H), 3.93-3.81 (m, 4H), 3.67 (s, 2H), 3.24-3.12 (m, 4H), 2.57 (q, $J = 6.9$ Hz, 2H), 1.59 (d, $J = 6.9$ Hz, 3H), 1.07 (t, $J = 6.9$ Hz, 3H); LCMS (M^+) 610, RT = 1.397 (column 2; run time: 4 min).

25

EXAMPLE 63

2-[3-(pyridin-4-ylmethyl)ethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.52-8.42 (m, 3H), 8.19 (dd, $J = 1.5, 8.1$ Hz, 1H), 7.41-7.19 (m, 7H), 6.35 (br d, $J = 7.3$ Hz, 1H), 5.27 (app quint, $J = 7.2$ Hz, 1H), 4.25 (s, 2H), 3.74-3.63 (m, 6H), 3.53-3.44 (m, 4H), 2.56 (q, $J = 7.2$ Hz, 2H), 2.44 (m, 2H), 1.60 (d, $J =$

30

6.6 Hz, 3H), 1.08 (t, $J = 7.2$ Hz, 3H); LCMS (M+) 624, RT = 1.113 (column 2; run time: 4 min).

EXAMPLE 64

5

(S)-2-[3-(4-morpholinylmethyl)pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(2,6-dimethyl-4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.50 (d, $J = 4.4$ Hz, 1H), 7.97 (d, $J = 7.3$ Hz, 1H), 7.41-7.20 (m, 2H), 6.94-6.78 (m, 3H), 6.30 (br d, $J = 6.2$ Hz, 1H), 5.23 (app quint, $J = 7.2$ Hz, 1H), 4.08 (s, 2H), 3.88-3.73 (m, 2H), 3.72-3.61 (m, 4H), 3.46 (d, $J = 12.1$ Hz, 2H), 2.59-2.48 (m, 4H), 2.42 (t, $J = 11.2$ Hz, 2H), 1.59 (d, $J = 7.0$ Hz, 3H), 1.26 (d, $J = 6.6$ Hz, 6H); LCMS (M+) 589, RT = 1.650 (column 2; run time: 4 min).

EXAMPLE 65

15

(S)-2-[3-(4-pyridinylmethyl)ethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(2,6-dimethyl-4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.44 (br s, 1H), 8.35 (br s, 1H), 7.37 (br s, 1H), 7.31-7.20 (m, 1H), 6.93-6.78 (m, 3H), 6.33 (br d, $J = 7.3$ Hz, 1H), 5.23 (app quint, $J = 7.2$ Hz, 1H), 4.26-4.09 (m, 2H), 3.87-3.72 (m, 2H), 3.50-3.40 (m, 2H), 2.99 (br s, 2H), 2.53 (br s, 2H), 2.42 (t, $J = 11.2$ Hz, 2H), 1.59 (d, $J = 6.6$ Hz, 3H), 1.26 (d, $J = 6.2$ Hz, 6H), 1.02 (app br s, 9H); LCMS (M+) 589, RT = 1.827 (column 2; run time: 4 min).

25

EXAMPLE 66

(S)-2-[3-(4-pyridinylmethyl)ethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(2,6-dimethyl-4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.53-8.42 (m, 3H), 8.18 (d, $J = 9.1$ Hz, 1H), 7.42-7.32 (m, 1H), 7.31-7.19 (m, 3H), 6.93-6.78 (m, 3H), 6.34 (br d, $J = 7.3$ Hz, 1H), 5.23 (app quint, $J = 7.2$ Hz, 1H), 4.24 (s, 2H), 3.88-3.71 (m, 2H), 3.67 (s, 2H), 3.52-3.41 (m, 2H), 2.56 (q, $J = 7.2$ Hz, 2H), 2.42 (t, $J = 11.0$ Hz, 2H), 1.59 (d, $J = 6.6$ Hz, 3H),

1.26 (d, $J = 6.2$ Hz, 6H), 1.07 (t, $J = 7.2$ Hz, 3H); LCMS (M^+) 638, RT = 1.693 (column 2; run time: 4 min).

EXAMPLE 67

5

(S)-2-[3-(4-morpholinylmethyl)pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.84-8.79 (m, 1H), 8.59 (dd, $J = 1.5, 4.8$ Hz, 1H), 8.49 (dd, $J = 1.7, 4.6$ Hz, 1H), 7.96 (d, $J = 7.0$ Hz, 1H), 7.86 (dt, $J = 7.3, 1.8$ Hz, 1H), 7.58-7.31 (m, 6H), 6.48 (br d, $J = 7.7$ Hz, 1H), 5.36 (app quint, $J = 7.2$ Hz, 1H), 4.08 (s, 2H), 3.71-3.58 (m, 4H), 2.57-2.45 (m, 4H), 1.65 (d, $J = 7.0$ Hz, 3H); LCMS (M^+) 553, RT = 1.217 (column 2; run time: 4 min).

EXAMPLE 68

15

(S)-2-[3-[ethyl(2-propyl)aminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.80 (d, $J = 1.8$ Hz, 1H), 8.57 (dd, $J = 1.5, 4.8$ Hz, 1H), 8.49-8.29 (m, 2H), 7.86 (dt, $J = 8.0, 1.8$ Hz, 1H), 7.59-7.29 (m, 6H), 6.56 (app br s, 1H), 5.35 (app quint, $J = 7.2$ Hz, 1H), 4.28-4.07 (m, 2H), 3.00 (app br s, 1H), 2.54 (br s, 2H), 1.65 (d, $J = 7.0$ Hz, 3H), 1.03 (app br s, 9H); LCMS (M^+) 553, RT = 1.413 (column 2; run time: 4 min).

EXAMPLE 69

25

(S)-2-[3-[(4-pyridinylmethyl)ethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 8.82 (d, $J = 2.2$ Hz, 1H), 8.65-8.56 (m, 1H), 8.55-8.42 (m, 3H), 8.18 (d, $J = 8.1$ Hz, 1H), 7.93-7.83 (m, 1H), 7.64-7.19 (m, 8H), 6.53 (br d, $J = 7.3$ Hz, 1H), 5.35 (app quint, $J = 7.2$ Hz, 1H), 4.24 (s, 2H), 3.66 (s, 2H), 2.55 (q, $J = 7.2$ Hz, 2H), 1.65 (d, $J = 6.6$ Hz, 3H), 1.07 (t, $J = 7.0$ Hz, 3H); LCMS (M^+) 602, RT = 1.273 (column 2; run time: 4 min).

30

EXAMPLE 70

2-[3-[ethyl(2-propyl)aminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300
5 MHz): δ 8.44 (d, *J* = 3.7 Hz, 1H), 8.35 (d, *J* = 8.1 Hz, 1H), 7.43-7.11 (m, 5H), 6.33 (br d, *J* = 6.2 Hz, 1H), 5.29 (app quint, *J* = 7.2 Hz, 1H), 4.15 (s, 2H), 3.05-2.91 (m, 1H), 2.52 (q, *J* = 6.8 Hz, 2H), 1.60 (d, *J* = 7.0 Hz, 3H), 1.07-0.93 (m, 9H); LCMS (M+) 560, RT = 2.160 (column 2; run time: 4 min).

10

EXAMPLE 71

2-[3-[diethylaminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300
MHz): δ 8.48 (d, *J* = 3.7 Hz, 1H), 8.27 (br s, 1H), 7.64-7.43 (m, 4H), 7.38 (dd, *J* =
15 4.4, 7.7 Hz, 1H), 6.42 (app br s, 1H), 5.32 (app quint, *J* = 7.2 Hz, 1H), 4.24 (br s, 2H), 2.64 (br s, 4H), 1.61 (d, *J* = 7.0 Hz, 3H), 1.06 (br s, 6H); LCMS (M+) 530, RT = 2.023 (column 2; run time: 4 min).

EXAMPLE 72

20

2-[3-[ethyl(2-propyl)aminomethyl]pyridin-2-yl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300
MHz): δ 8.44 (br s, 1H), 8.35 (br d, *J* = 6.6 Hz, 1H), 7.64-7.44 (m, 1H), 7.42-7.31
(m, 4H), 6.46-6.29 (app br s, 1H), 5.32 (app quint, *J* = 7.2 Hz, 1H), 4.15 (s, 2H),
25 3.07-2.89 (m, 1H), 2.61-2.44 (m, 2H), 1.62 (d, *J* = 7.0 Hz, 3H), 1.10-0.91 (m, 9H);
LCMS (M+) 544, RT = 2.093 (column 2; run time: 4 min).

EXAMPLE 73

30 (S)-2-(3-methylpyridin-2-yl)-4-(trifluoromethyl)-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-5-thiazolecarboxamide. ¹H NMR (CDCl₃, 300 MHz): δ 8.74 (d, *J* = 1.8 Hz, 1H), 8.52 (dd, *J* = 1.2, 4.5 Hz, 1H), 8.39 (dd, *J* = 1.2, 4.5 Hz,

1H), 7.83 (ddd, $J = 1.8, 2.2, 8.1$ Hz, 1H), 7.60-7.22 (m, 7H), 6.87 (br d, $J = 7.5$ Hz, 1H), 5.34 (app quint, $J = 7.2$ Hz, 1H), 2.72 (s, 3H), 1.63 (d, $J = 6.9$ Hz, 3H); LCMS (M+) 468, RT = 1.593 (column 4; run time: 3 min).

5

EXAMPLE 74

2-[3-(dimethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 7.85-7.78 (m, 1H), 7.42-7.16 (m, 7H), 6.48 (br d, $J = 6.6$ Hz, 1H), 5.28 (app quint, $J = 7.2$ Hz, 1H), 3.59 (s, 2H), 2.18 (s, 6H), 1.60 (d, $J = 6.9$ Hz, 3H); LCMS (M+) 517, RT = 2.207 (column 3; run time: 4 min).

10

EXAMPLE 75

15 2-[3-(dimethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-(3-trifluoromethylbenzyl)-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 7.86-7.79 (m, 1H), 7.43-7.18 (m, 7H), 6.56 (app br s, 1H), 4.66 (d, $J = 5.7$ Hz, 2H), 3.59 (s, 2H), 2.18 (s, 6H); LCMS (M+) 503, RT = 2.143 (column 3; run time: 4 min).

20

EXAMPLE 76

(S)-2-[3-(dimethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-(3-methoxyphenyl)ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 300 MHz): δ 25 7.80 (d, $J = 7.2$ Hz, 1H), 7.42-7.25 (m, 4H), 6.96-6.82 (m, 3H), 6.45 (br d, $J = 6.6$ Hz, 1H), 5.24 (app quint, $J = 7.2$ Hz, 1H), 3.81 (s, 3H), 3.61 (s, 2H), 2.19 (s, 6H), 1.59 (d, $J = 6.9$ Hz, 3H); LCMS (M+) 463, RT = 1.877 (column 3; run time: 4 min).

30

EXAMPLE 77

2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500

MHz): δ 7.68-7.21 (m, 8H), 6.42 (app br s, 1H), 5.28 (app quint, $J = 7.2$ Hz, 1H), 3.77 (s, 2H), 2.47 (q, $J = 7.0$ Hz, 4H), 1.61 (d, $J = 7.0$ Hz, 3H), 0.90 (t, $J = 7.0$ Hz, 6H); LCMS (M+) 547, RT = 1.383 (column 2; run time: 4 min).

5

EXAMPLE 78

2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 7.68-7.25 (m, 8H), 6.46 (app br s, 1H), 5.32 (app quint, $J = 7.0$ Hz, 1H), 3.77 (s, 2H), 2.47 (q, $J = 7.0$ Hz, 4H), 1.62 (d, $J = 7.0$ Hz, 3H), 0.90 (t, $J = 7.0$ Hz, 6H); LCMS (M+) 529, RT = 2.053 (column 2; run time: 4 min).

10

EXAMPLE 79

2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-(3-fluorobenzyl)-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 7.69-7.00 (m, 8H), 6.52 (app br s, 1H), 4.63 (d, $J = 5.5$ Hz, 2H), 3.92-3.70 (m, 2H), 2.63-2.38 (m, 4H), 1.05-0.83 (m, 6H); LCMS (M+) 465, RT = 1.743 (column 2; run time: 4 min).

15

20

EXAMPLE 80

2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-(3-trifluoromethoxybenzyl)-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 7.69-7.21 (m, 8H), 6.51 (s, 1H), 4.66 (d, $J = 6.0$ Hz, 2H), 3.77 (s, 2H), 2.47 (q, $J = 7.0$ Hz, 4H), 0.91 (t, $J = 7.0$ Hz, 6H); LCMS (M+) 531, RT = 2.030 (column 2; run time: 4 min).

25

EXAMPLE 81

(S)-2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(4-morpholinyl)phenyl]ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 7.67-7.26 (m, 6H), 6.91-6.83 (m, 3H), 5.22 (app quint, $J = 7.2$ Hz, 1H), 3.85 (t, J

30

= 4.5 Hz, 4H), 3.47 (s, 2H), 3.17 (t, J = 4.5 Hz, 4H), 2.63-2.37 (m, 4H), 1.61 (t, J = 6.7 Hz, 3H), 0.95 (m, 6H); LCMS (M+) 546, RT = 1.533 (column 2; run time: 4 min).

5













EXAMPLE 82





(S)-2-[3-(diethylaminomethyl)phenyl]-4-(trifluoromethyl)-N-[1-(3-methoxyphenyl)ethyl]-5-thiazolecarboxamide. ^1H NMR (CDCl_3 , 500 MHz): δ 7.67-7.27 (m, 6H), 6.96-6.82 (m, 3H), 5.24 (app quint, J = 7.0 Hz, 1H), 3.83-3.80 (m, 5H), 2.57-2.39 (m, 4H), 1.60 (d, J = 7.0 Hz, 3H), 1.07-0.80 (m, 6H); LCMS (M+) 491, RT = 1.797 (column 2; run time: 4 min).

Table 4. The following examples were also made by the above methods.

Example	Structure	Method/Run Time (min)	Retention Time (min)	MS (M+)
83		1/3	1.803	462
84		5/3	1.270	393
85		1/3	1.683	410
86		1/3	1.703	448
87		1/3	1.787	488
88		1/3	1.307	393
89		1/3	1.743	504
90		1/3	1.810	486
91		1/3	1.773	506
92		1/3	1.847	462
93		1/3	1.720	358

Example	Structure	Method/Run Time (min)	Retention Time (min)	MS (M+)
94		1/3	1.737	440
95		1/3	1.877	478
96		1/3	1.830	485
97		5/3	1.897	545
98		3/3	1.803	529
99		3/3	1.753	491
100		3/3	1.353	576
101		3/3	1.443	521
102		1/3	1.207	409
103		1/3	1.617	514
104		3/4	2.580	593
105		3/4	2.147	501
106		2/4	1.197	560
107		2/4	1.350	538
108		2/4	2.030	559

Example	Structure	Method/Run Time (min)	Retention Time (min)	MS (M+)
109		2/4	1.957	545
110		2/4	1.390	560
111		2/4	1.663	505
112		2/4	1.573	518
113		2/4	1.990	608
114		2/4	1.547	540
115		2/4	1.350	609
116		2/4	1.067	623
117		2/4	1.220	601
118		2/4	2.180	476
119				
120		2/3	1.900	502


Example	Structure	Method/Run Time (min)	Retention Time (min)	MS (M+)
121		2/3	1.963	521
122		2/4	1.560	561
123		1/4	2.067	609
124		1/4	1.980	544

Methods. solvent A: 10% MeOH/90% H₂O/0.1 % TFA; solvent B: 90% MeOH/10% H₂O/0.1 % TFA; run time (in minutes) is a gradient from 100%A to 100%B followed by 1 minute at 100%B. Column 1: YMC ODS-A 3.0 x 50 mm S7 C18; column 2: XTERRA 3.0 x 50 mm S7; column 3: YMC ODS-A C18 S5 4.6 x 33 mm; column 4: XTERRA C18 S5 4.6 x 50 mm; column 5 YMC C18 S5 4.6 x 50 mm.

CLAIMS

We claim:


- 5 1. A compound of Formula I



- 10 where:

Q^1 is CH or N;

Ar^1 is selected from the group consisting of




R^1 is hydrogen, C_{1-6} alkyl, hydroxymethyl, or trifluoromethyl;



- 20 R^2 is halogen, C_{1-6} alkyl, C_{1-2} perfluoroalkyl, C_{1-6} alkoxy, C_{1-2} perfluoroalkoxy, $-NR^6R^7$, $-(CH_2)_{1-4}NR^6R^7$, $-O(CH_2)_{2-3}NR^6R^7$, or pyridyl;

R^3 is hydrogen, halogen, or C_{1-6} alkoxy;

- 25 R^4 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, $-NR^6R^7$, $-(CH_2)_{1-4}NR^6R^7$, $-O(CH_2)_{2-3}NR^6R^7$, or



R^5 is hydrogen, halogen, or C_{1-6} alkoxy;

R^6 is hydrogen, C_{1-6} alkyl, $-C(=NH)NH_2$, , or ;

5 R^7 is hydrogen or C_{1-6} alkyl;


or R^6 and R^7 taken together are $-\text{CH}_2\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2\text{XCH}_2\text{CH}_2-$, where X is a chemical bond, CH_2 , CHOH , NH , NCH_3 , NCOCH_3 , O, or S;

10

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound of claim 1 where Q^1 is CH.

15 3. A compound of claim 1 where Ar^1 is



4. A compound of claim 3 selected from the group consisting of

20 2-(4-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

25 2-(2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

2-(2-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

30

2-(2-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

5 2-(2-methoxyphenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(3-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

10 N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(2-fluorophenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

15

N-[(3-fluorophenyl)methyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

20 2-(4-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(3,4-dimethoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

25 2-(2,4-dimethoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2,4-dimethoxyphenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

30

2-(2-methoxyphenyl)-N-[1-[3-(1-piperidiny)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-methoxyphenyl)-N-[1-[3-(1-pyrrolidinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

5 N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-fluorophenyl)-N-[1-[3-[(2-furanylmethyl)methylamino]phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

10 2-(3,4-dimethoxyphenyl)-N-[1-[3-(1-pyrrolidinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-fluorophenyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

15

N-[1-(3-aminophenyl)ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

20 N-[1-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

25 N-[1-[3-(dimethylamino)phenyl]ethyl]-2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

30

2-(5-fluoro-2-methoxyphenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(5-fluoro-2-methoxyphenyl)-N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-chlorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-chlorophenyl)-N-[1-[3-(dimethylamino)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-chlorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

2-(2-chlorophenyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-chlorophenyl)-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- 2-[2-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-[2-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[4-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(dimethylamino)methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(dimethylamino)methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(dimethylamino)methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- 2-[2-[(diethylamino)methyl]phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 5 2-[2-[(diethylamino)methyl]phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 10 2-(4-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-(2-methoxyphenyl)-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 15 N-[(3-fluorophenyl)methyl]-2-(3-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- N-[1-(2,3-dihydro-5-benzofuranyl)ethyl]-2-(3-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 20 2-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 25 2-(3,4-dimethoxyphenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-(3,4-dimethoxyphenyl)-N-[1-(3,4-dimethoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 30 2-(3,4-dimethoxyphenyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- 2-(3-fluorophenyl)-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-(2,4-dimethoxyphenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 5 2-(3-fluorophenyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 10 N-[1-(3-bromophenyl)ethyl]-2-(2-methoxyphenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[3-(4-morpholinyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 15 2-[3-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- N-[(1S)-1-(3-methoxyphenyl)ethyl]-2-[3-(4-morpholinyl)phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 20 2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 25 2-[2-[2-(diethylamino)ethoxy]phenyl]-N-[(1S)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- N-[1-(3-aminophenyl)ethyl]-2-(2-fluorophenyl)-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 30 2-[2-[2-(diethylamino)ethoxy]-5-fluorophenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

- 2-[2-[(dimethylamino)methyl]phenyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[(diethylamino)methyl]phenyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-(4-morpholinylmethyl)phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-(4-morpholinylmethyl)phenyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-(4-morpholinylmethyl)phenyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-(3-fluorophenyl)-N-[(3-fluorophenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-2-[2-(4-morpholinylmethyl)phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- N-[(1*S*)-1-(3-methoxyphenyl)ethyl]-2-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;
- 2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;


2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[2-[[ethyl(4-pyridinylmethyl)amino]methyl]phenyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(2-methylbenzoyl)-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide; and

N-[1-[4-fluoro-3-(4-morpholinyl)phenyl]ethyl]-2-(2-methylbenzoyl)-4-(trifluoromethyl)-5-thiazolecarboxamide.

15



5. A compound of claim 1 where Ar¹ is

6. A compound of claim 5 selected from the group consisting of

2-[3-[(diethylamino)methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

25

2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

30

N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

5 N-[(1*S*)-1-[3-[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]phenyl]ethyl]-2-[3-[[ethyl(4-pyridinyl)methyl]amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[3-(4-morpholinylmethyl)-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

10

2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

15

2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

20 2-[3-[(diethylamino)methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide;

25

2-(3-methyl-2-pyridinyl)-N-[(1*S*)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-(3-methyl-2-pyridinyl)-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

30

2-[3-(1,3-dioxolan-2-yl)-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;

2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-N-[(1*S*)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide;


2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide; and

2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide.


7. A compound of claim 1 where R¹ is methyl.

8. A compound of claim 1 where R¹ is hydrogen.

9. A compound of claim 1 where the structure is that of Formula Ig.



10. A compound of claim 1 where R¹ is C₁₋₆alkyl and the stereochemical configuration is that of Formula Ia.



11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

12. A method for treating disorders responsive to opening KCNQ potassium channels comprising administering to a patient a therapeutically effective amount of a compound of claim 1.

13. The method of claim 12 where the disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders.
- 5 14. The method of claim 12 where the disorder is migraine.
15. The method of claim 12 where the disorder is neuropathic pain.
16. The method of claim 12 where the disorder is bipolar disorder.
- 10 17. The method of claim 12 where the disorder is anxiety.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060281 A3

(51) International Patent Classification⁷: **C07D 277/587**

(21) International Application Number:
PCT/US2003/039351

(22) International Filing Date:
11 December 2003 (11.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/435,970 20 December 2002 (20.12.2002) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; P. O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

(72) Inventors: **BOY, Kenneth, M.**; 50R Deer Run Road,
Durham, CT 06422 (US). **WU, Yong-Jin**; 228 Devonshire
Lane, Madison, CT 06443 (US). **GUERNON, Jason, M.**;
270 Magee Drive, Hamden, CT 06514 (US).

(74) Agents: **EPPERSON, James et al.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
6 January 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS**



(57) Abstract: Novel 2-arylthiazole derivatives of Formula (I) are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/39351

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D: 277/587

US CL : 548/200

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 548/200

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,998,450 A (EICKEN et al) 7 December 1999, see entire document.	1-17

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 March 2004 (23.03.2004)

Date of mailing of the international search report

31 AUG 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Patricia L. Morris

Telephone No. (703) 308-1235